Goldman Sachs: Updated List of 23 Highest-Conviction Buys, Vertex Added, Interactive Brokers Removed

According to Trend Research, Goldman Sachs' September 1 research report indicated that the U.S. high-conviction list was updated this month; Vertex Pharmaceuticals was added, Interactive Brokers Group was removed, and the list remained at 23 stocks. All U.S. equity gains in August were concentrated in the first two trading days, after which the market entered a summer consolidation phase, with Nvidia's robust earnings failing to break the stalemate. The 10-year Treasury yield rose by 9 basis points from the start of the month, Brent crude was essentially flat, while gold, silver, and bitcoin gained 9%, 22%, and 24%, respectively. Vertex was the standout performer this month. Goldman Sachs believes the company has five billion-dollar-plus commercial opportunities spanning cystic fibrosis, pain management, kidney disease, hematology, and the endocrine field following its proposed acquisition of Crinetics. Market expectations for peak sales of povetacicept in IgAN stand at $3.2 billion, significantly below Goldman Sachs' $5.8 billion estimate. Outperformers included Estée Lauder, which rose 5.3% in August, and DoorDash, up 18.1%. Following a strong second quarter, TPG raised its FRE expectations by approximately 10%. Viking Holdings and Applied Materials came under pressure amid overly elevated expectations. The list is constructed based on bottom-up fundamental analysis, covering six major sectors: consumer, financials, healthcare, industrials, resources, and technology.